major tech and AI developments centered on infrastructure expansion, safety measures, chip supply, and commercial growth. Amazon advanced drone logistics and AI cloud metrics; OpenAI and Anthropic reported divergent financial and safety updates; Microsoft addressed a Copilot security issue; Nvidia saw limited H200 chip shipments to China; Samsung raised foundry prices amid AI demand; Apple adjusted App Store terms for EU compliance; Google expanded study tools and custom chip partnerships; and SpaceX explored potential deals while Moderna delivered strong vaccine trial news. Smaller or less-covered firms on the list had no prominent public updates today.
- Amazon / AWS: Announced expansion of Prime Air drone deliveries to nearly 500 U.S. cities and towns by year-end (a sixfold increase). AWS AI business reported passing a $25 billion annual revenue run rate with triple-digit year-over-year growth. Alexa+ AI features made free on compatible Fire TV devices in the U.S.
- Anthropic: Linked to a deal supporting UK chip startup Fractile’s ~$600M raise at a $6.5B valuation. Q2 sales reportedly more than doubled to ~$11.6B with a swing to small operating profit (outpacing OpenAI on growth metrics in some reports). Detailed experiments showing Claude accelerating protein design and chemical analysis, with plans for a scientist access program.
- Apple: Moving to change App Store terms for developers to resolve a long-running EU antitrust dispute (previously involving a large fine). Shares under pressure amid perceptions of slower AI positioning relative to peers; focus on premium iPhone 18 Pro Max revenue mix.
- Alphabet (Google): Announced new Gemini-powered study tools (student hub, notebooks, interactive 3D visualizations) plus student offers for AI plans. Expanded custom-chip collaboration with Marvell (including a large warrant structure). Reported interest in Spirit Airlines anonymized data for AI training.
- Microsoft: Released a patch for a critical one-click Copilot vulnerability (CVE-2026-24301 / “CoSnitch”) that enabled potential data exfiltration. Shares edged higher amid ongoing AI efficiency and profitability commentary.
- Nvidia: Small batches of H200 AI chips began reaching mainland China after limited easing of restrictions (with ByteDance and Tencent among early recipients in some reports). Discussed potential investments in startups; broader AI financing and capacity themes continued.
- OpenAI: Q2 sales grew ~18% QoQ to ~$6.7B (described as tepid vs. some peers) with larger losses; growth said to have accelerated in Q3. CFO indicated path to public company status in 2027 (or sooner). Tightened cyber-related monitoring and safeguards on advanced models (including ~20% compute overhead estimates for certain inference). Launched or prepared ChatGPT for Teens with age-appropriate features.
- Samsung Electronics: Raising advanced foundry prices by up to 15% as AI demand fills capacity (particularly 4nm lines); Chinese customers reported accepting larger increases. Related HBM and packaging strength noted in broader chip commentary.
- SpaceX: Approached Cognition about a potential acquisition (company declined and stated it is not for sale). Operational scale and related AI/hardware themes continued in coverage.
- TSMC: Capacity constraints highlighted by competitor pricing actions and sustained AI demand; shares relatively steady amid broader semiconductor moves.
- Broadcom: Faced pressure linked to Google’s expanded custom-chip work with Marvell and broader AI funding projections.
- AMD: Shares declined after efficiency forecasts for future AI racks; ongoing competitive positioning vs. Nvidia and custom silicon discussions.
- Intel: Shares weaker amid sector pressure; limited new positive catalysts reported today.
- Meta Platforms: Ongoing multi-state trial and related child-safety litigation coverage; broader AI and platform themes.
- Stripe: Told investors that early 2026 marked a major inflection (“beginning of the singularity”); H1 revenue up ~41% YoY. Separately linked to a large acquisition of OpenRouter in recent reports.
- Moderna: Shares surged sharply after positive late-stage trial results for a personalized mRNA cancer vaccine in combination with Merck’s Keytruda for melanoma.
